Thursday 16 October, 2025
Introduction: Immunotherapy approaches represent a promising paradigm for cancer treatment. This led to an explosion in the number of therapeutic…
Read moreAbstracts
Model-based optimal dosing regimen for recombinant hepatitis B human immunoglobulin (GC1102) in Chronic Hepatitis B Patients
Thursday 16 October, 2025
Objectives: To propose a model-based optimal dosing regimen of recombinant hepatitis B human immunoglobulin based on phase 1 clinical data…
Read morePopulation pharmacokinetics of FM101 in healthy volunteers and long-term safety prediction: phase 1 study
Thursday 16 October, 2025
Introduction/Objectives: Non-alcoholic steatohepatitis is a chronic liver disease characterized by hepatic steatosis, inflammation, and fibrosis. Currently, there are no approved…
Read morePopulation pharmacokinetics of ticagrelor and active metabolite during veno-arterial extracorporeal membrane oxygenation
Thursday 16 October, 2025
Objective: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is a mechanical method for supporting the cardiopulmonary systems usually used for treating cardiac…
Read moreA modelling framework for in vitro/in vivo translation of PROTACs PK/PD and PK/Efficacy: accelerating drug discovery of targeted protein degraders
Thursday 16 October, 2025
Objectives: PROTACs [1] are novel small molecules which violate not only the optimal, well-understood physicochemical design space [2], but also…
Read moreAn integrated modelling approach for targeted degradation: insights on optimisation, data requirements and PKPD predictions from semi- or fully-mechanistic models and exact steady state solutions
Thursday 16 October, 2025
Objectives: This work proposes a novel pragmatic modelling approach for targeted protein degradation which captures the essence of the mechanism…
Read morePopulation pharmacokinetics of levofloxacin in South African adults treated for rifampicin-resistant tuberculosis.
Thursday 16 October, 2025
Objectives: Rifampicin-resistant TB (RR-TB) is a global public health concern. Incident cases increased globally by 3% from 2020 to 2021…
Read morePopulation pharmacokinetics of delamanid in adults treated for rifampicin-resistant tuberculosis: effect of pregnancy.
Thursday 16 October, 2025
Objectives: Delamanid is a WHO-recommended drug for the treatment of RR-TB [1]. Delamanid has a terminal half-life of 30-38 h…
Read moreA framework for drug pharmacokinetics during cardiopulmonary bypass
Thursday 16 October, 2025
Objectives: Cardiopulmonary bypass (CPB) is an extracorporeal medical procedure that replaces heart and lung function. CPB can alter pharmacokinetic (PK)…
Read morePopulation pharmacokinetic modelling for vancomycin using Bayesian model averaging approach
Thursday 16 October, 2025
Introduction: Vancomycin has been used as a first-line standard treatment against methicillin-resistant Staphylococcus aureus for over 60 years [1]. More…
Read more